OBJECTIVE: Group B streptococcus (GBS) is the leading cause of neonatal sepsis in the US. As such, rectovaginal culture for all women between 35-37 weeks gestation is recommended to screen for those colonized with the pathogen. Early onset disease in neonates can be prevented by intrapartum antibiotic prophylaxis (IAP), but missed screening opportunities and false negative maternal cultures result in preventable neonatal disease. We sought to evaluate the cost-effectiveness of universal IAP in reducing neonatal morbidity and mortality related to GBS. STUDY DESIGN: A decision-analytic model was created using TreeAgePro; probabilities, costs, and utilities were derived from the literature. We compared universal screening with rectovaginal culture by 37 weeks gestation to no screening and IAP given to all women at delivery after 37 weeks. This model was applied to a theoretical cohort of 1,600,000 women with no documented penicillin allergy based on the estimated number of nulliparous, term-births annually in the United States. The cost-effectiveness threshold was set to $100,000 per quality adjusted life year (QALY). Univariate sensitivity analyses were used to evaluate the robustness of the results. RESULTS: In our theoretical cohort of 1.6 million women, we found that IAP given to all laboring women, no matter their GBS status, was cost effective when compared to IAP given to GBS positive women based on screening culture. Universal IAP results in 803 fewer cases of neonatal sepsis, 29 fewer cases of meningitis, 13 fewer cases of neurodevelopmental delay, and 24 fewer neonatal deaths, despite an increase in cases of maternal anaphylaxis, maternal death from anaphylaxis, and increased cost overall. The universal antibiotics strategy resulted in 1,134 additional QALYs and an incremental cost effectiveness ratio of $22,300/QALY. Univariate sensitivity analysis demonstrated that universal IAP was cost-effective when the cost of culture was between $16.75 and $48.25, and was cost-saving for culture cost above $48.25. CONCLUSION: Our findings suggest that the current standard of care for prenatal screening of GBS may not be cost-effective compared to prophylactically treating all women in pregnancy with penicillin. Further research is necessary to determine if a change in diagnostic test or screening strategy would improve maternal and neonatal outcomes. OBJECTIVE: Preventing fetal transmission of human cytomegalovirus (HCMV) is a major clinical challenge. Fetuses infected during the first trimester often experience short-and long-term complications including fetal growth restriction and cerebral palsy. Due to lack of suitable animal model, we aimed to develop a 3D in-vitro model of early human placental development that can be used to explore HCMV placental infection and fetal transmission. STUDY DESIGN: Human episomal-derived iPSCs were grown for 10 days to generate embryoid bodies, which were grown into placental organoids as adherent culture (2D differentiation) or in suspension culture (3D differentiation) using BMP4 and inhibitors of TGFb and FGF2 signaling for 11 days. On day 5 of differentiation, 3D organoids were exposed to HCMV strain AD169rUL131 (0.1 and 0.3 MOI units) tagged with green fluorescent protein (GFP). After 24h, organoids were thoroughly washed to remove the viral exposure. Morphology, surface marker expression, release of prototype placental hormones, and invasive phenotype were assessed using phase contrast and confocal microscopy, Western blot and ELISA. Organoids were grown on coverslips (migration) or atop matrigel (invasion) and analyzed at 0, 2, and 6 days post exposure to HCMV. Infection was quantified by analyzing recovered virions from placental organoids by rapid culture on human fibroblasts. RESULTS: Human iPSCs expressed cytotrophoblast markers CDX2, EOMES, and KRT-7 by day 3 of differentiation. Secretion of placental hormones hCG and CRH, invasive EVT phenotype, and surface HLA-G expression were observed by day 5. GFP expression was observed in HCMV-infected placental organoids confirming receptivity to the virus and infection (Figure) . Cell migration was temporally altered after infection. Infectious virions were recovered from placental organoids, indicating that virus can be transmitted from the infected placental organoids. The amount of infected virions varied non-linearly with trophoblast differentiation. CONCLUSION: Our findings demonstrate hiPSC can be used to characterize HCMV infection in placental organoids and support the notion that post-exposure to HCMV the infected placenta may represent a secondary reservoir of virus. This innovative system can be further used to study interventions interrupting transmission of congenital infections to the fetus.
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Human induced pluripotent stem cells (iPSCs) derived 3D model for early placental HCMV infections
Poster Session III OBJECTIVE: Buprenorphine (BUP) is the preferred medication for opioid maintenance therapy in pregnancy and is primarily metabolized in the liver. Given that hepatitis C virus (HCV) infection is common in opiate dependent individuals, we sought to determine whether liver dysfunction related to HCV infection impacts the dose of BUP needed during pregnancy. STUDY DESIGN: A retrospective cohort study of 266 pregnancies with antenatal exposure to BUP from 2015-2018 at a single center.
Individuals positive for HCV infection versus women negative for HCV infection were compared. For HCV prevalence, Kruskal-Wallis tests were performed with continuous variable and Chi-Square tests with categorical variables. Spearman correlation tests were used to assess the relationship between BUP dose and HCV status. RESULTS: In patients with antenatal exposure to BUP, the average age was 29 (18-42) years and 99% were Caucasian. HCV infection was present in 39% of the population. Patients with HCV infection required less dose increases throughout pregnancy (p¼0.02). Among the HCV positive cohort, a positive correlation was seen between HCV viral load and the liver enzymes AST (0.30, p¼0.003) and ALT (0.25, p¼0.01) . A negative correlation was noted among the HCV positive cohort for HCV viral load in relation to BUP dose during the second trimester (-0.27, p¼0.01) and third trimester (-0.20, p¼0.04) . CONCLUSION: HCV infection was associated with less of an increase in BUP dose throughout pregnancy compared to mothers without HCV infection. Among HCV positive mothers, a higher HCV viral load was correlated with higher liver enzymes as well as lower BUP doses during the second and third trimester. These findings may be due to HCV related liver inflammation that potentially decreases liver clearance of BUP. Larger prospective studies as well as pharmacokinetic studies will be useful in further delineating this relationship. C during labor at term ( 37 weeks). A retrospective reclassification of this cohort was made according to three different classifications of women with fever during labor: 1) classic "clinical chorioamnionitis" criteria; 2) "Triple I" criteria (ACOG 2016); and 3) "Intra-amniotic infection" criteria (ACOG 2017) . The designation between "Isolated Maternal Fever" and "Suspected Intraamniotic Infection" according to each classification is presented in Table 1 . The incidence of suspected intraamniotic infection according to the ACOG was also compared
